# A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

> **NCT04042116** · PHASE1,PHASE2 · SUSPENDED · sponsor: **Clovis Oncology, Inc.** · enrollment: 227 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Gynecologic Cancer

## Interventions

- **DRUG:** Lucitanib
- **DRUG:** Lucitanib
- **DRUG:** Lucitanib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04042116
- **Lead sponsor:** Clovis Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2019-07-29
- **Primary completion:** 2023-07
- **Final completion:** 2024-01
- **Target enrollment:** 227 (ESTIMATED)
- **Why stopped:** Company decision
- **Last updated:** 2022-12-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04042116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04042116, "A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04042116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*